Key facts
- Clerkenwell Health’s last known valuation is $17.3M (Apr 2025).
- It has raised $8.1M; the latest was Seed Round in Apr 2025.
- Notable investors include London & Partners., SyndicateRoom, Lionheart Ventures, Exceptional Ventures, SPRIM Global Investments — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Clerkenwell Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Clerkenwell Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Clerkenwell Health
Provider of pharma clinical research services intended to specialise in psychiatry and central nervous system (CNS) conditions. The company's healthcare clinic's therapy provides preparation, treatment sessions, and subsequent follow-up by experienced psychotherapists, helping healthcare with robust and clinically validated data sets to prove the efficacy of psilocybin-assisted therapy versus existing standards of care.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 30
- Website
- clerkenwellhealth.com/
- Ownership
- Privately Held (backing)
Clerkenwell Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clerkenwell Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clerkenwell Health in its N-PORT filings yet. We sweep new filings monthly.